The progression of non-culprit coronary lesion is related to higher SII, SIRI, and PIV in patients with ACS Authors: Zhou Yilu, Wang Zhanglong, Huang Fanke, Guan Jing, Wang Yue, Chen Yuwen, Li Bingqing, Lv Jianfeng Published: 2024 ABSTRACT Coronary heart disease pathogenesis is intricately linked to inflammation. Acute coronary syndrome (ACS) is a coronary heart disease that seriously affects the prognosis of patients. New immune-inflammatory indices such as systemic immune inflammation index (SII), system inflammation response index (SIRI), and pan-immune-inflammation value (PIV) have emerged as potential biomarkers, offering reflection into systemic inflammatory states and assisting in the prognosis of diverse diseases. This research explored the association between the new immune-inflammatory indices (SII, SIRI, and PIV) and the progression of non-culprit coronary lesions (NCL) in patients with ACS after percutaneous coronary intervention (PCI). Our study investigated the potential association between the immune-inflammatory index (SII, SIRI, and PIV) and NCL progression in patients with ACS following PCI. We conducted a retrospective analysis of patients with ACS who underwent PCI twice at a single-center from 2019 to 2023. Clinical and angiographic features were collected from electronic medical records. The primary outcome was NCL progression. All patients were divided into a progression group and a non-progression group based on angiographies. The clinical and angiographic features were analyzed. The study included 311 ACS patients (progression group: 97 males, 34 females; non-progression group: male 146 males, 34 females). The SII, SIRI, and PIV were significantly higher in the NCL progression group than in the non-progression group (P < .001). Logistic regression analysis showed that SII, SIRI, and PIV were independent risk factors for the NCL progression and positively correlated with it (OR: 1.002, P < .001; OR: 2.188, P < .001; OR: 1.003, P < .001). ROC showed that the SII value was the highest in terms of sensitivity with a value of 67.18% (AUC = 0.7288, P < .001), and the SIRI was the highest in terms of specificity with a value of 79.44% (AUC = 0.6974, P < .001). The SII, SIRI, and PIV are valuable predictors of NCL progression in patients with ACS. Higher SII, SIRI, and PIV are related to the progression of NCL. 1. Introduction Cardiovascular diseases are the leading causes of death worldwide.[1] Acute coronary syndrome (ACS) is a group of syndromes of acute myocardial ischemia and necrosis caused by partial or complete stenosis and occlusion of the coronary artery lumen after atherosclerotic plaque rupture or thrombosis.[2] Although percuraneous coronary intervention (PCI)can restore myocardial blood perfusion and relieve symptoms in the shortest time, it is aimed at treating culprit lesions and ignores the treatment of non-culprit coronary lesion (NCL). Previous studies have shown that major adverse cardiovascular events (MACE) after PCI involve the progression of NCL.[3] Different from PCI only for culprit coronary lesion (CL), PCI for NCL can significantly reduce the poor prognosis when it achieves complete revascularization.[4] The rapid progress of NCL after PCI may be one of the reasons for the decrease of PCI benefit.[5] Many studies show that vulnerable plaques in ACS patients exist not only in CL but also in NCL.[6,7] When occurs ACS or after PCI, the body has a rapid increase in the inflammatory response, which may be closely related to the progress of NCL. Recently, there has been a concern about the role of low-grade inflammatory injury in the disease process. Some scholars believe that patients with systemic inflammatory diseases have a higher risk of cardiovascular diseases.[8] The role of immune-inflammatory system activation in the development of atherosclerotic plaques has been assumed. Based on previous studies, the Immune-inflammatory system causes endothelial dysfunction through oxidative modification, phagocytosis, adhesion migration, and thrombosis, which plays an important role in the development of atherosclerosis.[9–14] Therefore, the markers of immune inflammation have become a research hotspot. The number of inflammatory cells in the blood routine and its derived indexes are the core factors of inflammatory reaction. A series of new indicators, such as SII, SIRI, and PIV have been studied in various systems in recent years, especially in tumor and surgical patients, because of their simplicity and availability. However, the correlation between the new immune-inflammatory markers SII, SIRI, and PIV in the progression of noncriminal vascular diseases after PCI has not been fully studied. In a retrospective cohort of ACS patients who have undergone PCI, we aimed to explore the relationship between new immune-inflammatory indexes SII, SIRI, and PIV and the progress of NCL, and to explore the value of these indexes in predicting the progress of NCL. 2. Methods 2.1. Patient selection This retrospective study conformed to the Declaration of Helsinki and was approved by the Ethics Committee in the Renhe Affiliated Hospital of China Three Gorges University. All patients underwent PCI as a treatment for the CL. Patients with coronary heart disease (CHD) who previously received PCI in the cardiovascular medicine of our hospital from January 2019 to December 2023 were retrospectively studied. The inclusion criteria were: age ≥ 18 years old; All patients were given aspirin, clopidogrel, or tigrellol before the operation; and there were no contraindications for coronary angiography (CAG), and carotid ultrasound. The exclusion criteria were as follows: Patients with severe heart failure (NYHA III or IV), severe myocarditis, and congenital heart disease; Life-threatening patients with tumors, infectious diseases, or severe liver and kidney diseases; For the first time, CAG indicated that all 3 main coronary arteries were completely occluded; the history of coronary artery bypass grafting surgery; and incomplete clinical and laboratory data. Finally, a total of 331 patients were enrolled in this study. 2.2. Data collection and definition All patients` clinical data and laboratory were obtained from hospital medical records. It includes sociodemographic characteristics, medical history, and laboratory results derived from hospital medical records. Blood samples were measured on the day of admission or the next day, encompassing fasting blood glucose (FBG), neutrophils, monocytes, lymphocytes, platelets, creatinine, uric acid (UA), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). 2.3. Angiogram and analysis CAG imaging analysis and the definitions of progression in NCL. All patients underwent multi-position projection. The angiographic images were independently analyzed by 2 cardiologists with more than ten years of experience unaware of the patient’s clinical information. The vessels treated by PCI were defined as culprit lesions. All patients underwent PCI for the culprit lesions. Those vessels that were not associated with ischemic symptoms or positive functional ischemia tests and did not require PCI at baseline were defined as NCL. Definition of NCL progression[15]: The stenosis degree of the NCL was ≥ 50% at the time of baseline PCI, and the degree of NCL progression was ≥ 10% at the time of angiographic follow-up; The stenosis degree of the NCL was < 50% at the time of baseline PCI, and the degree of NCL progression was ≥ 30% at the time of angiographic follow-up; The degree of NCL progression ≥ 30%, while there were no NCL at the time of baseline PCI; and NCL progression to total occlusion. The NCL progression group was further divided into mild (n = 85), moderate (n = 25), and severe progressive groups (n = 21) according to the degree of progress. The degree of stenosis increased by <50%, 50% to 70%, and more than 70% respectively. When multiple NCL progressions were found, the lesions with the most significant increase in stenosis grade in the follow-up were taken as the index lesions. SII was calculated as (neutrophil count [109/L]) · (platelet count [109/L])/ (lymphocyte count [109/L]); SIRI was (neutrophil count [109/L]) · (monocyte count [109/L])/ (lymphocyte count [109/L]); PIV was calculated as (neutrophil count [109/L]) · (platelet count [109/L]) · (monocyte count [109/L])/(lymphocyte count [109/L]).[16] The severity of coronary lesions was quantitatively evaluated by the Gensini score assessment system and scored by 2 independent senior cardiologists. The degree of stenosis and the coronary artery lesion site were scored as follows: 1 point for ≤ 25% narrowing, 2 points for 26% to 50% narrowing, 4 points for 51% to 75% narrowing, 8 points for 76% to 90% narrowing, 16 points for 91% to 99% narrowing, and 32 points for total occlusion. After that, each lesion score is multiplied by a factor considering the importance of the lesion’s position in the coronary circulation. The final integral, which represents the degree of coronary artery disease of each patient, is obtained by summing the integrals of each branch.[17] 2.4. Statistical analysis All statistical analyses were performed using Prism 9.0 (GraphPad) and SPSS v26.0 (IBM Corp.). Continuous variables were examined by the Kolmogorov–Smirnov test. Continuous variables are expressed as mean ± SD and categorical data are presented as percentages. Differences in continuous variables between the 2 groups were assessed by unpaired 2-tailed t-test and the Mann–Whitney U-test, as appropriate. Categorical data and proportions were analyzed by chi-square test. Correlations between the inflammation indies (SII, SIRI, and PIV) and the Gensini score were analyzed with bivariate correlation. Binary logistic regression analysis was performed to examine independent risk factors for the progression of NCL. Receiver operating characteristic (ROC) analysis and a calculation of sensitivity and specificity were performed to test the ability of indices to predict the progression of NCL. For the multivariate regression analysis, the parameters with a P < .1 in the univariate analysis were included in the model. The effects of different variables in the progressive group were calculated with univariate analysis. 2-tailed P < .05 was considered statistically significant. 311 patients were divided into 2 groups: the progression group (n = 131) and the non-progression group (n = 180) by the definition of NCL progression (Fig. 1). Patients with CHD who previously received PCI in the cardiovascular medicine of our hospital from January 2019 to December 2023 were retrospectively studied. The inclusion criteria were age ≥ 18 years old; all patients were given aspirin, clopidogrel, or tigrellol before the operation; there were no contraindications for CAG, and carotid ultrasound. The exclusion criteria were as follows: Patients with severe heart failure (NYHA III or IV), severe myocarditis, and congenital heart disease. Life-threatening patients with tumors, infectious diseases, or severe liver and kidney diseases. For the first time, CAG indicated that all 3 main coronary arteries were completely occluded. The history of coronary artery bypass grafting surgery. Incomplete clinical and laboratory data. Finally, a total of 331 patients were enrolled in this study. CAG = coronary angiography, CHD = coronary heart disease, NYHA = New York Heart Association, PCI = percutaneous coronary intervention. 3. Results 3.1. Baseline clinical characteristics Of the 331 patients, the progression group was observed in 131 (42.12%). Patients in the progression group were older (65.0 > 61.5, P = .043) and more smoking (63.4%>50.6%, P = .025). Men were more in both groups (74%, 81%). No significant difference existed in previous history of hypertension, diabetes, and ischemic stroke. The use of statins is more in the nonprogressive group (P < .001). The baseline clinical characteristics of the patients are shown in Table 1 Table 1Demographics and clinical characteristics of the patient.VariableProgression (n = 131)Non-progression (n = 180) t/χ 2 P Men gender (%)97 (74.0)146 (81.1).137Age (%)65.0 (56.0, 70.0)61.5 (53.0, 69.0)−2.020 .043 BMI (kg/m2)24.60 ± 0.3123.55 ± 0.24−2.702 .007 Hypertension (%)91 (69.5)116 (64.4).354Hyperlipidemia (%)22 (16.8)36 (20.0).474Diabetes mellitus (%)48 (36.6)50 (27.8)2.760 .097 Ischemic stroke (%)51 (38.9)54 (30.0).100Smoking (%)83 (63.4)91 (50.6)5.043 .025 Drinking (%)54 (41.2)82 (45.6).447Aspirin (%)12 (94.7)176 (97.8).141Beta-blockers (%)73 (55.7)110 (61.1).341Calcium antagonists (%)43 (32.8)67 (37.2).423Nitrates (%)13 (9.9)22 (12.2).527ACEI/ARB (%)59 (45.7)83 (46.1).851Statins (%)110 (84.0)174 (96.7)15.418 <.001 ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, BMI = body mass index. Demographics and clinical characteristics of the patient. ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, BMI = body mass index. Significant differences in laboratory results were observed between the progression group and the non-progression group. The progression group exhibited elevated neutrophils, FBG, TG, and LDL-C levels, while lymphocytes and HDL-C levels were significantly lower compared to the non-progression group (P < .05). No significant differences were observed in other laboratory findings such as monocytes, platelets, creatinine, UA, and TC. SII, SIRI, and PIV were significantly higher in the progressive group (all P < .05) (Table 2). In the progression group, there were 85 (64.9%) patients with mild to moderate stenosis, 25 (19.1%) patients with mild to severe stenosis, and 21 (16.0%) patients with moderate to severe stenosis. Among the tertiles of SII, the progress rate is 19.8%, 26.7%, and 53.4%. For SIRI, the progress rate is 21.4%, 26.7%, and 51.9%. About PIV, the progress rate is 25.2%, 26.0%, and 48.9% (Fig. 2). Table 2Laboratory characteristics.VariableProgression (n = 131)Non-progression (n = 180)z/χ2 P Neutrophils (109/L)4.37 (3.57, 5.42)3.48 (2.82, 4.23)−5.594<.001Monocytes (109/L)0.38 (0.30, 0.48)0.38 (0.29, 0.47).974Lymphocytes (109/L)1.10 (0.92, 1.41)1.40 (22.2, 26.4)−6.023<.001Platelet (109/L)182.56 ± 53.55176.50 ± 51.29.426Creatinine (μmol/L)77.2 (63.6, 90.3)75.7 (65.3, 88.7).917Uric acid (μmol/L)359.39 ± 111.47347.35 ± 90.87.311FBG (mmol/L)5.90 (5.27, 7.18)5.51 (5.16, 6.20)−3.028.002TC (mmol/L)3.55 (3.01, 4.53)3.52 (3.06, 4.08).176TG (mmol/L)1.33 (0.96, 2.06)1.16 (0.84, 1.49)−3.245.001HDL-C (mmol/L)1.10 (0.97, 1.32)1.20 (1.03, 1.47)−2.547.011LDL-C(mmol/L)1.73 (1.34, 2.27)1.62 (1.28, 1.97)−2.356.018SII668.22 (439.48, 1052.47)435.55 (289.76, 562.45)−6.89<.001SIRI1.47 (0.94, 2.24)0.92 (0.60, 1.32)−5.934<.001PIV259.99 (139.84, 430.39)161.44 (96.44, 248.23)−5.298<.001FBG = fasting blood glucose, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index, TC = total cholesterol, TG = triglyceride. Laboratory characteristics. FBG = fasting blood glucose, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index, TC = total cholesterol, TG = triglyceride. In the progression group, there were 85 (64.9%) patients with mild to moderate stenosis, 25 (19.1%) patients with mild to severe stenosis, and 21 (16.0%) patients with moderate to severe stenosis. Among the tertiles of SII, the progress rate is 19.8%, 26.7%, and 53.4%. For SIRI, the progress rate is 21.4%, 26.7%, and 51.9%. About PIV, the progress rate is 25.2%, 26.0%, and 48.9%. PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index. The median interval between 2 angiograms in the progressive group and nonprogressive group is respectively 384 and 374 days. Gensini score 2 was significantly higher in the progressive group (25.0 > 10.0, P < .001) (Fig. 3). ΔGS in the progressive group was less than that in the nonprogressive group (16.0 < 22.0, P = .002). Left anterior descending lesions were common in the 2 groups (96.2%, 88.3%), especially in the progression group (P = .014). The rate of restenosis was not different between patients with progression and those without (Table 3). Table 3Angiographic findings.VariableProgression (n = 131)Non-progression (n = 180) z/χ 2 P Intervals between CAG, d374.0 (259.0, 802.0)374.0 (288.0, 490.8).107Vascular lesions (%) Single61 (46.6)94 (52.2).325 Multi70 (53.4)86 (47.8)Lesion site, n (%) LAD126 (96.2)159 (88.3)−2.467 .014 LCX58 (38.2)71 (41.1).393 RCA46 (35.1)72 (37.2).703Gensini score142.0 (24.0, 58.0)40.0 (24.0, 59.0).994Gensini score225.0 (12.5, 40.0)10.0 (5.0, 22.0)−6.852 <.001 ΔGS16.0 (7.5, 33.0)22.0 (11.0, 41.5)−3.143.002Restenosis (%)41 (31.3)46 (25.6).265CAG = coronary angiography, Gensini score1 = Gensini score after primary PCI, Gensini score2 = Gensini score after second PCI, LAD = left anterior descending coronary artery, LCX = left circumflex artery, RCA = right coronary artery, PCI = percutaneous coronary intervention, ΔGS = Gensini score1-Gensini score2 . Angiographic findings. CAG = coronary angiography, Gensini score1 = Gensini score after primary PCI, Gensini score2 = Gensini score after second PCI, LAD = left anterior descending coronary artery, LCX = left circumflex artery, RCA = right coronary artery, PCI = percutaneous coronary intervention, ΔGS = Gensini score1-Gensini score2 . Gensini score 2 was significantly higher in the progressive group (25.0 > 10.0, P < .001). 3.2. Multivariate logistic regression analysis The independent determinants of NCL were identified using univariate and multivariate logistic regression analyses. In the univariate analysis, variables such as age, BMI, smoking, Gensini score2, TG, TC, HDL, LDL, FBG, SII, SIRI, and PIV were associated with the NCL. The multivariate logistic regression analysis revealed that age, smoke, SII.SIRI and PIV were independent predictors of the NCL (Table 4). Table 4Multivariate analysis of risk factors for lesion progression.VariableUnivariate analysisMultivariate analysisOR95% CI P OR95% CI P Age1.0271.003, 1.052.0291.0431.013, 1.073.004BMI1.0971.025, 1.176.0081.0640.979, 1.156.147DM1.5040.928, 2.436.0971.1940.648, 2.200.569Smoke1.6911.067, 2.679.0251.8441.073, 3.169.027TC1.3491.066, 1.706.0130.8770.445, 1.728.705TG1.7241.244, 2.390.0011.4841.000, 2.203.05HDL-c0.4340.207, 0.912.0280.6940.230, 2.096.518LDL-c1.8291.290, 2.594.0011.9640.818, 4.712.131FBG1.1941.055, 1.352.0051.0810.937, 1.247.286SII*1.0021.002, 1.003<.0011.0021.001, 1.003<.001SIRI*2.2381.653, 3.030<.0012.1881.587, 3.018<.001PIV*1.0031.002, 1.005<.0011.0031.002, 1.005<.001BMI = body mass index, DM = diabetes mellitus, FBG = fasting blood-glucose, HDL-c = high-density lipoprotein cholesterol, LDL-c = low-density lipoprotein cholesterol, PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index, TC = total cholesterol, TG = triglyceride.* To prevent multicollinearity, analysis was carried out separately with these parameters. Multivariate analysis of risk factors for lesion progression. BMI = body mass index, DM = diabetes mellitus, FBG = fasting blood-glucose, HDL-c = high-density lipoprotein cholesterol, LDL-c = low-density lipoprotein cholesterol, PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index, TC = total cholesterol, TG = triglyceride. To prevent multicollinearity, analysis was carried out separately with these parameters. 3.3. Bivariate correlations In ACS patients, the scatter plot in Figure 4 illustrates the relationship between the SII, SIRI, or PIV and Gensini score. It had a positive linear association. Inflammatory markers (SII, SIRI, and PIV) were correlated with the Gensini score (R = 0.143, P = .011, R = 0.190, P = .001, and R = 0.207, P < .001, respectively) (Table 5). Table 5Bivariate correlations between inflammatory markers and Gensini score.Variable r P SII0.143.011SIRI0.190.001PIV0.207<.001Abbreviations: PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index. Bivariate correlations between inflammatory markers and Gensini score. Abbreviations: PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index. In ACS patients, the scatter plot illustrates the relationship between the SII, SIRI, or PIV and Gensini score. It had a positive linear association. ACS = acute coronary syndrome, PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index. 3.4. Predictive value of SII, SIRI, and PIV for NCL progression ROC analysis was conducted for the progressive group patients, it showed that, with a cutoff value of >543.4 for SII, it predicted the NCL progression with 67.18% sensitivity and 72.22% specificity (AUC = 0.7288 [95% CI: 0.6711–0.7865], P < .001). For SIRI, a cutoff value of 1.355 predicted the NCL progression with a sensitivity of 54.96% and a specificity of 79.44% (AUC = 0.6974 [95% CI: 0.6379–0.7568], P < .001). For PIV, a cutoff value of 250.6 had 53.44% sensitivity and 76.11% specificity in predicting the NCL progression in patients with ACS (AUC = 0.6759 [95% CI: 0.6152–0.7366], P < .001) (Table 6, Fig. 5). Table 6ROC curve for NCL progression.VariableAUC P Cut offSensitivitySpecificitySII0.7288<.0001543.467.18%72.22%SIRI0.6974<.00011.35554.96%79.44%PIV0.6759<.0001250.653.44%76.11%Abbreviations: PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index. ROC curve for NCL progression. Abbreviations: PIV = pan-immune-inflammation value, SII = systemic immune inflammation index, SIRI = system inflammation response index. ROC curve of SII, SIRI, and PIV of NCL progression. The area under curve of SII is 0.7288, 95 CI: 0.6711, 0.7865. The area under curve of SIRI is 0.6974, 95 CI: 0.6974, 0.7568; The area under curve of PIV is 0.6759, 95 CI: 0.6152, 0.7366. NCL = non-culprit coronary lesion, PIV = pan-immune-inflammation value, ROC = receiver operating characteristic, SII = systemic immune inflammation index, SIRI = system inflammation response index. 4. Discussion We examined the levels of SII, SIRI, and PIV in the NCL progression group and the NCL non-progression group. Our findings indicated that SII, SIRI, and PIV levels in the NCL progression group are significantly higher than those in patients in the NCL non-progression group. Further investigation suggests that SII is the best in predicting the degree of vascular stenosis in NCL progression. At present, the research on the progress mechanism of NCL mostly focuses on inflammatory reaction,[9] lipogenic theory,[3] oxidative stress theory,[18] and hyper-homocysteinemia theory.[19] Compared with other studies, this study mainly discusses the relationship between 3 new immune-inflammatory markers in the progress of NCL and adopts a cross-sectional study. Most existing studies adopt prospective studies, and the endpoints are readmission, re-PCI treatment, MACE incidence, or mortality. This study can preliminarily evaluate the progress of NCL after PCI through inflammatory markers, providing strong evidence for early intervention by clinicians. Many patients with recurrent MACE after PCI was not associated with implanted stents but were attributed to the appearance of NCL progression and vulnerable plaques.[20,21] Atherosclerosis is still the pathological basis of the progression of NCL, and its rapid plaque progression has become 1 of the primary problems facing patients after PCI.[22] Although using lipid-lowering drugs such as statins in clinics is beneficial in delaying the progress of atherosclerotic plaque, it is difficult to stop the progress of plaque lesions. Cutlip et al[20] pointed out that after 1 year of standardized treatment for low-risk people, the annual average risk rate of NCL accidents was 1.7%, and the annual average risk rate of NCL accidents was 6.3%, which was significantly higher than the incidence of CL. Varenhorst et al[21] found that the risk of recurrent myocardial infarction in untreated NCL was twice as high as in previous stent treatment. Therefore, the progress of NCL is closely related to the recurrence of cardiovascular adverse events, which seriously affects the long-term prognosis of patients after PCI. New immune-inflammatory markers can quantify some immune and inflammatory components in the body, including several inflammatory indicators that are easy to obtain and cheap.[23] Neutrophils are one of the important subtypes of white blood cells, which are closely related to inflammatory reactions and can accelerate all stages of atherosclerosis.[24] It is mainly by promoting monocyte recruitment, macrophage activation, and cytotoxicity.[10] Monocytes can migrate and transform into macrophages when inflammation occurs, and secrete enzymes to promote the instability of fibrous cap and participate in plaque rupture.[12,25] Many interventions have been proven to protect myocardial function after acute myocardial infarction by promoting the transition of monocytes/macrophages from pro-inflammatory phenotype to anti-inflammatory phenotype.[26,27] Lymphocytes play an important role in developing atherosclerotic plaques, and lymphocytes participate in thrombosis when plaques rupture.[28] The increase in platelet level may be related to the development and progress of CHD.[29–31] As the cornerstone of the prevention and treatment of acute cardiovascular events, the benefits of antiplatelet drugs mainly come from their anti-aggregation effect and anti-inflammatory off-target effect.[14] Previous studies have shown lower lymphocyte count is associated with higher cardiovascular disease risk.[32] The higher neutrophil to lymphocyte ratio at admission also indicates that patients have a higher inflammatory response. Avci et al[33] found that neutrophil to lymphocyte ratio was a valuable index in predicting the risk of hospital death of ST segment elevation myocardial infarction patients. Based on this, it is necessary to study the relationship between the new inflammatory indicators composed of the above indicators and the progress of NCL. Many studies have confirmed that SII is a valuable predictor, which can predict the development trend of coronary artery disease,[34] no-reflow phenomenon of ACS patients,[35] the occurrence of preeclampsia in pregnant women,[36] but also evaluate the load of thrombus.[37] SIRI was associated with the diagnosis and had the highest values for patients with ACS.[38] For acute type A aortic dissection, SIRI is significantly associated with the short-term and long-term prognosis of patients who underwent emergency. Sen et al[39] showed that blood flow damage after PCI was related to high PIV before operation. In addition, Kaplangoray et al[40] found that PIV is related to slow coronary blood flow. This shows that SII, SIRI, and PIV can be used as indicators to identify the risk of cardiovascular disease in individuals. In this study, the data of 311 patients with ACS after PCI were analyzed. The interval between PCI was about 1.05 years, and the progress of NCL was observed in 42.1% of patients. First of all, our results show that the levels of SII, SIRI, and PIV in patients in the NCL progression group are significantly higher than those in patients in the NCL non-progression group. Secondly, when we compare the progress rate of NCL, we find that higher levels of SII, SIRI, and PIV are related to the increase in NCL progress rate. Secondly, when comparing the progress rate of NCL, we found that higher levels of SII, SIRI, and PIV were related to the increase in NCL progress rate. In addition, our analysis shows that after multivariate Logistic regression, SII, SIRI, and PIV are still independent predictors of NCL progress. This suggests that immune-inflammatory indexes (SII, SIRI, and PIV) can promote the progress of NCL in ACS patients after PCI. Finally, we compared the predictive efficacy of SII, SIRI, and PIV in predicting the degree of coronary artery stenosis in patients with NCL progression after PCI, and found that SII had the highest AUC and the best predictive efficiency. In addition, through bivariate correlation, SII, SIRI, and PIV were positively correlated with the Gensini score, among which PIV had the strongest correlation. Gensini score is a comprehensive score to evaluate the angiographic load and severity of CHD patients. It is reported that the Gensini score is closely related to the atherosclerotic plaque load assessed by intravascular ultrasound.[41] Therefore, the evaluation of NCL plaque in this study is reasonable. It can be seen that in ACS patients with elevated SII, SIRI, and PIV, the higher the Gensini score, the more severe the corresponding coronary stenosis and the more severe the plaque load. Our research shows that SII is more closely related to the progress of NCL than other markers. This is different from the existing research point of view. At present, it is generally believed that the influence of more parameters (such as PIV with 4 parameters) can increase the value of biomarkers,[42,43] but our research has not found it. Perhaps this is related to PIV and long-term prognosis. Smoking and blood lipid-related indicators are independent risk factors for atherosclerosis, which can lead to the progression of NCL by regulating inflammation and immune response, which is consistent with previous studies.[3,44] Additionally, diabetes mellitus is an independent risk factor for coronary artery disease. Berry et al[45] found that FBG, HbA1c, and diabetes history were related to the severity and progress of coronary atherosclerosis. Wang et al[46] conducted a follow-up study involving 205 patients with acute myocardial infarction concluding that FBG serves as an independent predictor of NCL progress in ST segment elevation myocardial infarction patients after direct PCI, our study also found that FBG and diabetes mellitus history were in NCL in CHD patients after PCI. Although ACS is mainly caused by the rupture or erosion of criminal plaques, we should also pay attention to the progress of noncriminal vascular plaques. In this study, we compare the performance of SII, SIRI, and PIV, and find that the AUC of SII is the best in predicting the progress of NCL. For ACS patients treated by PCI, we can simply calculate the values of SII, SIRI, and PIV to evaluate the progress of patients’ noncriminal blood vessels. For patients with higher SII, we can have more reasons to check optical coherence tomographythrough PCI to determine the situation of NCL plaque and effectively prevent the occurrence of acute adverse cardiovascular events. Consistent with these findings, our study also demonstrates that FBG and a history of diabetes mellitus are significant factors in the presence of NCL among patients with ACS. 5. Research limitations This study has several limitations. First, this study is a single-center retrospective analysis with a relatively small sample size, requiring further randomized prospective controlled study. Secondly, the lack of detailed vascular imaging data prevents a comprehensive assessment of the plaque. Third, blood samples were collected at the time of patient admission without dynamic observation of clinical outcomes. Fourth, the relationship between inflammatory markers of different types of ACS for the progression of NCL in patients was not further evaluated. 6. Conclusion SII, SIRI, and PIV served as independent predictors of NCL progression, and the predictive value of SII was moderate. The Higher SII, SIRI, and PIV are Related to the Progression of NCL. Author contributions Data curation: Zhou Yilu, Wang Zhanglong, Huang Fanke, Guan Jing, Wang Yue, Chen Yuwen, Li Bingqing. Formal analysis: Wang Zhanglong, Zhou Yilu. Methodology: Zhou Yilu Visualization: Zhou Yilu. Writing – original draft: Zhou Yilu. Writing – review & editing: Yilu Zhou, Lv Jianfeng.